Literature DB >> 19133192

[Four years experience in the follow up of nursing children with urolithiasis].

Martha Medina-Escobedo1, Carolina Medina-Escobedo, Gloria Martín-Soberanis, Salha Villanueva-Jorge, Arsenio Hernández-Flota.   

Abstract

OBJECTIVE: to describe clinical data, metabolic profile, treatment and evolution of a nursing children cohort with urolithiasis.
METHODS: using a descriptive, prospective and longitudinal design, were registered all patients with urolithiasis, of Pediatric Division at the Hospital General "Agustín O'Horán," in Yucatan, Mexico. We included all patients who were 36 months old and younger. We did not include children with malformations or associated disease which causes urolithiasis. Clinical and metabolic profiles, evaluation of the applied treatment as well as an evolution by four years period were done.
RESULTS: 63 patients were recruited with ages ranging from 2 to 36 months; 39 (61.9 %) were male. The most common clinical signs were crying upon urination (49.2 %), urinary retention (31.7 %), hematuria (30.2 %), and pollakiuria (28.6 %). Calculus were most frequently located in the kidney (58.7 %). The most common complications were acute urinary tract infection (61.9 %), malnutrition (47.6 %) and acute renal failure (12.7 %). Documented metabolic alterations included hyperuricosuria (57.1 %), hypomagnesiuria (11.1 %) and hypercalciuria (9.5 %).
CONCLUSIONS: urolithiasis should be suspected in children with crying upon urination and urinary symptoms; it should be considered among the different causes of renal failure; hyperuricosuria was the most frequent metabolic alteration.

Entities:  

Mesh:

Year:  2008        PMID: 19133192

Source DB:  PubMed          Journal:  Rev Med Inst Mex Seguro Soc        ISSN: 0443-5117


  1 in total

1.  Metabolic abnormalities and polymorphisms of the vitamin D receptor (VDR) and ZNF365 genes in children with urolithiasis.

Authors:  Martha Medina-Escobedo; Lizbeth González-Herrera; Salha Villanueva-Jorge; Gloria Martín-Soberanis
Journal:  Urolithiasis       Date:  2014-07-25       Impact factor: 3.436

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.